First Tracks Biotherapeutics Inc Reports Q3 2026 Net Loss of $0. ...
ANB033 Celiac Disease Data and a $200 Million Private Placement Anchor a Quarter of Clinical Progress and Strategic Repositioning Related Stocks: TRAX ,
ANB033 Celiac Disease Data and a $200 Million Private Placement Anchor a Quarter of Clinical Progress and Strategic Repositioning Related Stocks: TRAX ,